These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21647691)

  • 1. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
    Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
    Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
    Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
    Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
    Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
    Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
    Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
    Santini D; Martini F; Fratto ME; Galluzzo S; Vincenzi B; Agrati C; Turchi F; Piacentini P; Rocci L; Manavalan JS; Tonini G; Poccia F
    Cancer Immunol Immunother; 2009 Jan; 58(1):31-8. PubMed ID: 18458903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
    Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of phosphoantigen stimulation of human Vgamma9/Vdelta2 T cell clones include Th0 cytokines.
    Sireci G; Champagne E; Fourniè JJ; Dieli F; Salerno A
    Hum Immunol; 1997 Dec; 58(2):70-82. PubMed ID: 9475336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
    Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
    J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
    Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
    Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Vgamma9/Vdelta2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1).
    Eberl M; Engel R; Aberle S; Fisch P; Jomaa H; Pircher H
    J Leukoc Biol; 2005 Jan; 77(1):67-70. PubMed ID: 15498816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease.
    Triolo G; Accardo-Palumbo A; Dieli F; Ciccia F; Ferrante A; Giardina E; Sano CD; Licata G
    Arthritis Res Ther; 2003; 5(5):R262-8. PubMed ID: 12932289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
    Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M
    Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
    Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
    Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.
    Oyoshi MK; Nagata H; Kimura N; Zhang Y; Demachi A; Hara T; Kanegane H; Matsuo Y; Yamaguchi T; Morio T; Hirano A; Shimizu N; Yamamoto K
    Am J Pathol; 2003 May; 162(5):1629-38. PubMed ID: 12707047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominance of Vgamma9/Vdelta2 T lymphocytes in the cerebrospinal fluid of children with tuberculous meningitis: reversal after chemotherapy.
    Dieli F; Sireci G; Di Sano C; Champagne E; Fourniè JJ; Salerno JI
    Mol Med; 1999 May; 5(5):301-12. PubMed ID: 10390546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.